Sep 16, 2020 / 06:45PM GMT
Marissa Elizabeth Bych - Morgan Stanley, Research Division - Research Associate
Good morning for those of you on the West Coast and good afternoon for those on the East Coast. This is Marissa Bych with Morgan Stanley medtech equity research. And I'm back again with now, Brian Andrews, the CFO and Treasurer of Cooper Companies; and Kim Duncan, the VP of Investor Relations. Brian and Kim, it's great to have you with us. I think this is the first time we've had you for a live presentation at our Morgan Stanley healthcare conference. So hopefully, the first of many and hopefully in person next year. We'll see. But great to have you here.
Questions and Answers:
Marissa Elizabeth Bych - Morgan Stanley, Research Division - Research AssociateThere are a number of dynamics, I think, we should talk about today. We can talk about kind of near-term COVID-19 recovery and then some of the new product launches. MiSight, most importantly, has been a focus. And maybe get into some of the financials as well.
But let's just start with the nearer term, if that's
Trustpilot
